Despite its identification over a decade ago, p52 NF-kB (also known as NF-kB2 and Lyt-10) is one of the least understood NF-kB subunits (Neri et al., 1991; Schmid et al., 1991; Bours et al., 1992) . Similar to p50/p105 NF-kB, p52 is generated by proteolytic processing of its precursor p100 (Heusch et al., 1999) . Also like p105, p100 is cytoplasmic, contains IkB-like ankyrin repeats in its carboxy-terminus and can function as an inhibitor of other NF-kB subunits (Perkins, 2000) . p52 is found in the nucleus and can also freely homo-or heterodimerize with other NF-kB subunits but has a number of properties that distinguish it from other NF-kB family members. Unlike p105, stimuli such as lymphotoxin b, lipopolysaccharide, CD40 signaling and BAFF ligand induce processing of p100 to p52 (Coope et al., 2002; Dejardin et al., 2002; Kayagaki et al., 2002; Mordmuller et al., 2003; Muller and Siebenlist, 2003) . This results from phosphorylation-induced ubiquitination of p100 mediated by NF-kB-inducing kinase (NIK) and IkB kinase (IKK) a activity (Senftleben et al., 2001) ( Figure 1 ). p100, but not p52 or other NF-kB subunits, has also been reported to contain a death domain and stimulate apoptosis . The p52/p100 gene is also NF-kB regulated (Liptay et al., 1994) . p52-containing complexes have therefore been reported appearing at later time points following an NF-kBactivating stimulus (Muller and Siebenlist, 2003; Saccani et al., 2003) . Although p52 homodimers lack a transactivation domain they can stimulate transcription in conjunction with the Bcl-3 coactivator protein, which despite having ankyrin repeats resembling an IkB protein is found in the nucleus (Bours et al., 1993; Nolan et al., 1993) . p52 homodimers also have a distinct DNA-binding specificity to p50 and the other NF-kB subunits. They bind poorly to the 'consensus' Ig/HIV kB sequence used by many researchers to investigate NF-kB activity (Duckett et al., 1993) . Although p52 homodimers bind with higher affinity to the palindromic H2 kB element, this is still weaker than that seen for many other NF-kB subunits to their consensus sequences (Fujita et al., 1992; Duckett et al., 1993) , suggesting the 'true' binding site has yet to be found. This may have led to p52 being under-reported in the literature since its presence cannot be so easily detected. A result of this is the relative paucity of bona fide, p52 homodimer, target genes.
Perhaps, the most intriguing difference between p52/p100 and other NF-kB subunits is that the gene was also isolated as a result of its association with rearrangements of the 10q24 locus, found in some B-and T-cell lymphomas (Fracchiolla et al., 1993; Thakur et al., 1994; Chang et al., 1995) . These mutations have the effect of deleting part of the C-terminus of p100, resulting in a truncated form of the protein found constitutively in the nucleus, although these truncations are larger than p52 itself (Chang et al., 1995) . Significantly, these tumorassociated truncations have transforming effects in murine fibroblasts not seen with either p52 or p100 themselves (Ciana et al., 1997) . Interestingly, the p52 coactivator protein Bcl-3 is also a proto-oncogene and was originally identified in chronic lymphocytic leukemias at the breakpoint in the t(14;19) translocation (Michaux et al., 1996; McKeithan et al., 1997) .
It is now apparent that NF-kB subunits in general have important roles in tumorigenesis and in the response to cancer therapy (Baldwin, 2001; Garg and Aggarwal, 2002) . Aberrantly active NF-kB has been reported in many transformed cells and primary tumors (Baldwin, 2001; Garg and Aggarwal, 2002) . Moreover, NF-kB is activated by chemotherapeutic agents and ionizing radiation, where its antiapoptotic activity has an inhibitory effect on the efficacy of these treatments (Baldwin, 2001) . NF-kB has also been suggested to have a more wide-ranging role in tumor progression and its activity is also associated with angiogenesis and metastasis (Baldwin, 2001; Garg and Aggarwal, 2002) . Thus, NF-kB collectively has many oncogene-like characteristics. Furthermore, NF-kB has been shown to be required for the transforming properties of many oncogenes such as Bcr-Abl, Ras and the HTLV I protein Tax (Mayo et al., 1997; Mosialos, 1997; Reuther et al., 1998; Jo et al., 2000) . Among these studies, data to support a role for p52 in tumorigenesis, independent of chromosomal translocations, has been described. For example, in human clinical breast tumor samples, both p52 and Bcl-3 were found to be overexpressed (Cogswell et al., 2000) and a dramatic increase in p52 expression has also been observed in mouse skin tumors (Budunova et al., 1999) .
A molecular mechanism that can explain the oncogenic characteristics of p52 and Bcl-3 was recently discovered when the Cyclin D1 promoter was identified as a p52/Bcl-3 target gene (Westerheide et al., 2001) . Furthermore, another recent report indicates that p52 can also stimulate Bcl-2 expression (Viatour et al., 2003) . p52, Bcl-3 and Cyclin D1 are all found overexpressed in breast tumors (Weinstatsaslow et al., 1995; Cogswell et al., 2000) and p52/p100 expression correlates with Bcl-2 levels in human breast cancer tissue (Viatour et al., 2003) . Significantly, IKKa, which regulates processing of p100 NF-kB to p52 (Senftleben et al., 2001) , is also required for proliferation of mammary gland epithelial cells and Cyclin D1 expression . Together, these observations suggest a compelling hypothesis for how aberrant activation of p52 and Bcl-3, mediated by IKKa and resulting in increased expression of Cyclin D1 and Bcl-2, could provide an oncogenic stimulus in breast tumors. In partial support of this hypothesis, targeted deletion of the p100 C-terminus, to produce constitutively active p52, results in mice that appear normal at birth but develop multiple pathologies, resulting from gastric and lymphoid hyperplasia (Ishikawa et al., 1997) . While this result is consistent with the proproliferative role ascribed for p52 in cancer, these mice die postnatally preventing longer-term studies on cancer development.
The timely appearance of the article by Eliopoulos et al. in this edition of Oncogene therefore adds to and extends the evidence for the role of p52 in tumor development. The association of NF-kB with viral proteins has been known for a number of years (Mosialos, 1997) . NF-kB activity has been subverted by many viruses, such as human immunodeficiency virus 1 (Nabel and Baltimore, 1987) , to regulate their own replication. Moreover, many virally encoded proteins are activators of NF-kB (Mosialos, 1997). These include Figure 1 Schematic diagram depicting the activation and function of the p52/p100 NF-kB subunit. p52 is derived by cotranslational proteolytic processing of its precursor p100. This effect is induced by phosphorylation of p100 resulting from IKKa and NIK activity. In contrast, IKKb phosphorylates IkB proteins resulting in the activation of other NF-kB subunit complexes including p50/RelA. The EBV protein, LMP1, stimulates p100 processing in an NIK-dependent manner. Significantly, high levels of p52 are found in the nucleus of LMP1-expressing primary tumor biopsies. Loss of IKKg, the regulatory subunit required for the integrity of the IKK complex, does not affect LMP1 induced p52 formation, suggesting a novel mechanism of activation. Following activation, p52 can form complexes with other NF-kB subunits, or as a homodimer, interact with the transcriptional activator and proto-oncogene Bcl-3 in the nucleus of the cell. p52 target genes are not well characterized but include Cyclin D1. Induction of the tumor suppressor p53 can counteract the 'oncogenic' effects of p52 activation by inducing its association with the histone deacetylase HDAC1, resulting in the repression of Cyclin D1 expression. p52, Bcl-3 and Cyclin D1 are all found overexpressed in breast tumors, suggesting this regulatory mechanism is clinically important and could be exploited therapeutically. RHD ¼ Rel homology domain. ANK ¼ ankyrin repeats EBV-encoded LMP1 protein that has been known to be an activator of 'classical' p50/RelA(p65) NF-kB heterodimers for a number of years (Laherty et al., 1992) . Moreover, these effects are associated with the oncogenic effects of LMP1 (Cahir-McFarland et al., 1999) . Since EBV is frequently detected in a number of human tumors, including Hodgkin's disease, nasopharyngeal carcinomas and Burkitt's lymphoma, these effects are of direct clinical relevance. Eliopoulos and co-workers have demonstrated that in addition to its other effects on NF-kB, LMP1 can stimulate processing of p100 NF-kB to p52. This is more than an in vitro phenomena, since they also demonstrate that in LMP1-expressing, EBV-infected, biopsy samples from patients with Hodgkin's lymphoma and nasopharyngeal carcinoma, p52 can be found at high levels in the nucleus of the tumor cells. LMP1-activated p52 associates with both the RelA(p65) and RelB NF-kB subunits. p52 is most often described as a heterodimer with RelB or c-Rel, possibly due to the role all these subunits play in B-cell function, so it is interesting to see a definitive example of a p52/RelA heterodimer. Since p52/RelA heterodimers have been shown to have promoter-specific effects, distinct from those of p50/RelA complexes (Perkins et al., 1994) , it can be expected that the NF-kB-mediated genetic program in response to LMP1 might differ significantly from that found with TNF, for example, where processing of p100 to p52 is not induced (Mordmuller et al., 2003) . Using p52 null mouse embryo fibroblasts, Eliopoulos demonstrates that the absence of p52 significantly reduces the functional NF-kB response to LMP1 in reporter gene assays. Importantly, with respect to p52's role as a tumor promoter, LMP1-mediated induction of the Cyclin D1 promoter is virtually abolished in p52 null cells.
Similar to CD40, lymphotoxin b-, lipopolysaccharideand Tax-induced processing of p100 (Coope et al., 2002; Dejardin et al., 2002; Mordmuller et al., 2003; Muller and Siebenlist, 2003) , this report demonstrates that NIK is required for the LMP1-induced production of p52 (Figure 1) . Furthermore, IKKg (NEMO), the regulatory subunit of the IKK complex is not required for LMP1 processing of p100 to p52, although it is required for IkBa degradation. This makes LMP1 distinct from other viral oncoproteins, such as Tax, which can also induce p52 but by an IKKg-dependent process ). Since IKKg is required for the assembly of an active IKK complex, this could suggest that the LMP1-induced processing of p100 to p52 might also be IKKa independent. It should be noted, however, that loss of IKKg did not inhibit the IKKa-dependent stimulation of p100 processing by lymphotoxin b (Dejardin et al., 2002; Muller and Siebenlist, 2003) , indicating that IKKa can function independent of the rest of the IKK complex under these circumstances. A definitive resolution of this issue for LMP1 would require experiments in IKKa null cells, but this is left tantalizingly unanswered in this report.
The Eliopoulos data support the hypothesis that p52 is a tumor-promoting transcription factor whose processing can be induced by viral oncoprotein expression. It will be very interesting to extend these studies to include activated cellular oncoproteins. This is not the only aspect to p52 function, however. My laboratory recently discovered that the tumor suppressor p53 can induce the association of p52 with the histone deacetylase HDAC1, concomitant with the downregulation of Bcl-3 protein (Rocha et al., 2003) . This had the effect of converting p52 homodimers from being activators of the Cyclin D1 promoter to becoming repressors (Figure 1 ). In effect, p52 can be recruited to the p53 tumor suppressor program and contribute to cell cycle arrest. It will be interesting if Eliopoulos et al. extend their studies to examine the effects of LMP1 on Bcl-3 and endogenous Cyclin D1 expression. This paper did not examine p52 homodimer function but it would be consistent with the expected effects of LMP1 if there was also an increase in p52/Bcl-3 complexes. LMP1 and other oncoproteins might also inhibit the effects on p52 of p53 and other tumor suppressors.
The results of Eliopoulos et al., together with those of other laboratories in recent years, mean that p52 will undoubtedly take a more central role in our models of NF-kB-dependent tumorigenesis. Although much remains to be discovered and understood about its function, it is clear that its days of being the forgotten NF-kB subunit are coming to an end.
